Cancer

New treatment for non-Hodgkin lymphoma approved

(HealthDay)—Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma.

Cancer

Attacking lymphoma at the source

Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes, or B cells. Like cells in all cancers, the B cells begin to grow out of control, creating tumors in the lymph nodes, ...

Immunology

The STING of death in T cells

The cells of the innate immune system use a signaling pathway comprising STING (Stimulator of interferon genes) to detect DNA from invading viruses and fight them. However, it is unknown if STING triggers the same or different ...

Medical research

3-D organoids allow tests of lymphoma treatments

Cornell researchers have engineered a 3-D lymphoma organoid – a tissue culture that mimics the complex environment of lymphomas allowing scientists to study non-Hodgkin lymphomas – a technology that promises to rapidly ...

Cancer

Dose analysis predicts non-Hodgkin lymphoma survival

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...

Cancer

TCE exposure linked to increased risk of some cancers

Trichloroethylene (TCE) exposure has possible links to increased liver cancer risk, and the relationship between TCE exposure and risks of cancers of low incidence and those with confounding by lifestyle and other factors ...

Cancer

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

page 1 from 4